- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | TransCode Therapeutics leistet Vorauszahlung von 840.975 US-Dollar auf Wandelanleihe | 3 | Investing.com Deutsch | ||
| 28.09. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.09. | TransCode Therapeutics, Inc.: TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up | 190 | PR Newswire | Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors
In the 14 efficacy-evaluable patients:
71.4% stable disease... ► Artikel lesen | |
| 16.09. | RedChip Companies, Inc.: Join Today's Live Investor Webinar with TransCode Therapeutics | 410 | ACCESS Newswire | Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the... ► Artikel lesen | |
| 11.09. | CFO-Wechsel bei Transcode Therapeutics: Fitzgerald tritt zurück, Tattory übernimmt interimistisch | - | Investing.com Deutsch | ||
| 11.09. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | TransCode Therapeutics CFO retires | 1 | Seeking Alpha | ||
| 03.09. | RedChip Companies, Inc.: Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer | 361 | ACCESS Newswire | Learn how TransCode Therapeutics is advancing RNA therapeutics, cancer vaccines, and immuno-oncology programs designed to address advanced and metastatic cancersManagement to discuss TTX-MC138, the... ► Artikel lesen | |
| 07.08. | RedChip Companies, Inc.: Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 982 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small... ► Artikel lesen | |
| 03.08. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | 283 | PR Newswire | TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA... ► Artikel lesen | |
| 01.06. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer | 862 | PR Newswire | BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment... ► Artikel lesen | |
| 22.05. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 660 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 409 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,30 | +0,12 % | BioNTech SE: BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt | MAINZ, Deutschland, 20. Oktober 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 3. November 2026, die Ergebnisse für das dritte Quartal 2026... ► Artikel lesen | |
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| VALNEVA | 2,464 | -0,32 % | Valneva mit SONDERMELDUNG: Diese brandneue Prognose ändert einfach alles - Jetzt handeln, noch vor Börsenschluss! | ||
| NOVAVAX | 9,710 | -0,92 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 5,550 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| BRAIN BIOTECH | 2,730 | -0,73 % | SONDERMELDUNG bei BRAIN Biotech: Unsere Experten vergeben eine 3 - das ist der Grund! | ||
| VIVOSIM LABS | 0,179 | +1,13 % | VivoSim Labs, Inc.: VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling | ||
| OCUGEN | 0,719 | -1,10 % | Ocugen, Inc. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,728 | +1,89 % | Inovio wins case in dispute with VGXI, GeneOne Life Science | ||
| COSCIENS BIOPHARMA | 5,360 | -0,92 % | Cosciens Biopharma Inc (2): Cosciens raises $12M of up to $20M debenture deal | ||
| VIVORYON THERAPEUTICS | 0,910 | +0,22 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,780 | +1,45 % | H.C. Wainwright bekräftigt Verkaufsempfehlung für Sarepta Therapeutics - Kursziel 5 US-Dollar | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,866 | -2,30 % | PacBio, Verily Health Ink Multi-Year Deal to Scale Multi-Read Genomic Data for Biomedical AI | ||
| REDHILL BIOPHARMA | 0,455 | -1,13 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,41 % bei einem Aktienkurs von 1,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.